The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The standard of care for men with metastatic CRPC in 2010 following progression on docetaxel
is cabazitaxel or abiraterone acetate/prednisone. Based on results from two other studies,
cabazitaxel and prednisone has become a standard second line chemotherapy regimen and becomes
the backbone upon which to improve upon. Thus, the primary objective of this study is to
determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone
based on safety and tolerability in men with chemorefractory metastatic castration-resistant
prostate cancer (CRPC).